PuSH - Publikationsserver des Helmholtz Zentrums München

Fuchs, A.* ; Gliwinski, M.* ; Grageda, N.* ; Spiering, R.* ; Abbas, A.K.* ; Appel, S.* ; Bacchetta, R.* ; Battaglia, M.* ; Berglund, D.* ; Blazar, B.* ; Bluestone, J.A.* ; Bornhaeuser, M.* ; ten Brinke, A.* ; Brusko, T.M.* ; Cools, N.* ; Cuturi, M.C.* ; Geissler, E.* ; Giannoukakis, N.* ; Golab, K.* ; Hafler, D.A.* ; van Ham, S.M.* ; Hester, J.* ; Hippen, K.* ; Di Ianni, M.* ; Ilic, N.* ; Isaacs, J.* ; Issa, F.* ; Iwaszkiewicz-Grzes, D.* ; Jaeckel, E.* ; Joosten, I.* ; Klatzmann, D.* ; Koenen, H.* ; Van Kooten, C.* ; Korsgren, O.* ; Kretschmer, K. ; Levings, M.* ; Marek-Trzonkowska, N.M.* ; Martínez-Llordella, M.* ; Miljkovic, D.* ; Mills, K.H.G.* ; Miranda, J.P.* ; Piccirillo, C.A.* ; Putnam, A.L.* ; Ritter, T.* ; Roncarolo, M.G.* ; Sakaguchi, S.* ; Sanchez-Ramon, S.* ; Sawitzki, B.* ; Sofronic-Milosavljevic, L.* ; Sykes, M.* ; Tang, Q.* ; Vives-Pi, M.* ; Waldmann, H.* ; Witkowski, P.* ; Wood, K.J.* ; Gregori, S.* ; Hilkens, C.M.U.* ; Lombardi, G.* ; Lord, P.* ; Martinez-Caceres, E.M.* ; Trzonkowski, P.*

Minimum information about T regulatory cells: A step toward reproducibility and standardization.

Front. Immunol. 8:1844 (2018)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Cellular therapies with CD4+ T regulatory cells (Tregs) hold promise of efficacious treatment for the variety of autoimmune and allergic diseases as well as posttransplant complications. Nevertheless, current manufacturing of Tregs as a cellular medicinal product varies between different laboratories, which in turn hampers precise comparisons of the results between the studies performed. While the number of clinical trials testing Tregs is already substantial, it seems to be crucial to provide some standardized characteristics of Treg products in order to minimize the problem. We have previously developed reporting guidelines called minimum information about tolerogenic antigen-presenting cells, which allows the comparison between different preparations of tolerance-inducing antigen-presenting cells. Having this experience, here we describe another minimum information about Tregs (MITREG). It is important to note that MITREG does not dictate how investigators should generate or characterize Tregs, but it does require investigators to report their Treg data in a consistent and transparent manner. We hope this will, therefore, be a useful tool facilitating standardized reporting on the manufacturing of Tregs, either for research purposes or for clinical application. This way MITREG might also be an important step toward more standardized and reproducible testing of the Tregs preparations in clinical applications.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Korrespondenzautor
Schlagwörter Minimum Information Model ; T Regulatory Cells ; Immunotherapy ; Good Manufacturing Practice ; Cell Therapy ; Immune Tolerance; Chimeric Antigen Receptor; Versus-host-disease; Adoptive Transfer; In-vitro; Transplantation; Blood; Expansion; Allograft; Tolerance; Therapies
ISSN (print) / ISBN 1664-3224
e-ISSN 1664-3224
Zeitschrift Frontiers in Immunology
Quellenangaben Band: 8, Heft: , Seiten: , Artikelnummer: 1844 Supplement: ,
Verlag Frontiers
Verlagsort Lausanne
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Pancreatic Islet Research (IPI)